Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis
© 2023 Wiley-VCH GmbH..
Although stimulator of interferon genes (STING) agonists has shown great promise in preclinical studies, the clinical development of STING agonist therapy is challenged by its limited systemic delivery. Here, positively charged fusogenic liposomes loaded with a STING agonist (PoSTING) are designed for systemic delivery and to preferentially target the tumor microenvironment. When PoSTING is administered intravenously, it selectively targets not only tumor cells but also immune and tumor endothelial cells (ECs). In particular, delivery of STING agonists to tumor ECs normalizes abnormal tumor vasculatures, induces intratumoral STING activation, and elicits robust anti-tumor T cell immunity within the tumor microenvironment. Therefore, PoSTING can be used as a systemic delivery platform to overcome the limitations of using STING agonists in clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Small (Weinheim an der Bergstrasse, Germany) - 19(2023), 43 vom: 20. Okt., Seite e2300544 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Go, Eun-Jin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.10.2023 Date Revised 26.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/smll.202300544 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35882916X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35882916X | ||
| 003 | DE-627 | ||
| 005 | 20231226075558.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/smll.202300544 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM35882916X | ||
| 035 | |a (NLM)37381624 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Go, Eun-Jin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.10.2023 | ||
| 500 | |a Date Revised 26.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley-VCH GmbH. | ||
| 520 | |a Although stimulator of interferon genes (STING) agonists has shown great promise in preclinical studies, the clinical development of STING agonist therapy is challenged by its limited systemic delivery. Here, positively charged fusogenic liposomes loaded with a STING agonist (PoSTING) are designed for systemic delivery and to preferentially target the tumor microenvironment. When PoSTING is administered intravenously, it selectively targets not only tumor cells but also immune and tumor endothelial cells (ECs). In particular, delivery of STING agonists to tumor ECs normalizes abnormal tumor vasculatures, induces intratumoral STING activation, and elicits robust anti-tumor T cell immunity within the tumor microenvironment. Therefore, PoSTING can be used as a systemic delivery platform to overcome the limitations of using STING agonists in clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a positively charged liposomes | |
| 650 | 4 | |a stimulator of interferon genes (STING) | |
| 650 | 4 | |a systemic delivery | |
| 650 | 4 | |a tumor angiogenesis | |
| 650 | 4 | |a vascular normalization | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 700 | 1 | |a Yang, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Wooram |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Seung Joon |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Jun-Hyeok |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, So Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Won Suk |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Dong Keun |e verfasserin |4 aut | |
| 700 | 1 | |a Chon, Hong Jae |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Chan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Small (Weinheim an der Bergstrasse, Germany) |d 2005 |g 19(2023), 43 vom: 20. Okt., Seite e2300544 |w (DE-627)NLM167400452 |x 1613-6829 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:43 |g day:20 |g month:10 |g pages:e2300544 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/smll.202300544 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 43 |b 20 |c 10 |h e2300544 | ||